EFM
E Fund Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $621K | Sell |
12,764
-884
| -6% | -$43K | 0.03% | 206 |
|
|
2025
Q1 | $464K | Buy |
13,648
+1,863
| +16% | +$63.4K | 0.02% | 236 |
|
|
2024
Q4 | $464K | Sell |
11,785
-1,951
| -14% | -$76.8K | 0.02% | 237 |
|
|
2024
Q3 | $645K | Buy |
13,736
+2,648
| +24% | +$124K | 0.03% | 174 |
|
|
2024
Q2 | $599K | Buy |
11,088
+5,597
| +102% | +$302K | 0.03% | 162 |
|
|
2024
Q1 | $374K | Sell |
5,491
-3,969
| -42% | -$271K | 0.02% | 240 |
|
|
2023
Q4 | $592K | Buy |
9,460
+303
| +3% | +$19K | 0.04% | 131 |
|
|
2023
Q3 | $416K | Buy |
9,157
+1,863
| +26% | +$84.6K | 0.03% | 164 |
|
|
2023
Q2 | $409K | Sell |
7,294
-1,642
| -18% | -$92.1K | 0.03% | 162 |
|
|
2023
Q1 | $404K | Buy |
8,936
+308
| +4% | +$13.9K | 0.03% | 163 |
|
|
2022
Q4 | $351K | Buy |
8,628
+1,515
| +21% | +$61.6K | 0.03% | 207 |
|
|
2022
Q3 | $465K | Buy |
7,113
+245
| +4% | +$16K | 0.04% | 135 |
|
|
2022
Q2 | $417K | Buy |
+6,868
| New | +$417K | 0.04% | 182 |
|